MacroGenics, Janssen Biotech sign second deal for preclinical cancer candidate
MacroGenics Inc. licensed Johnson & Johnson's Janssen Biotech Inc. global rights to its preclinical bispecific candidate MGD015 for treating hematological malignancies and solid tumors.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.